Synovus Financial Corp Buys 3,356 Shares of Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Synovus Financial Corp lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 307,807 shares of the company’s stock after purchasing an additional 3,356 shares during the period. Johnson & Johnson accounts for approximately 0.6% of Synovus Financial Corp’s holdings, making the stock its 26th largest holding. Synovus Financial Corp’s holdings in Johnson & Johnson were worth $39,810,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Phocas Financial Corp. raised its stake in Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after buying an additional 125,161,066 shares during the period. Nuveen Asset Management LLC raised its stake in Johnson & Johnson by 5,447.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock worth $2,357,266,000 after buying an additional 16,619,550 shares during the period. Thoroughbred Financial Services LLC raised its stake in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after buying an additional 3,986,071 shares during the period. Renaissance Technologies LLC raised its stake in Johnson & Johnson by 145.5% during the 2nd quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after buying an additional 2,572,695 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 11.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after buying an additional 2,204,757 shares during the period. Institutional investors and hedge funds own 72.25% of the company’s stock.

Shares of JNJ traded up $1.57 during midday trading on Friday, hitting $133.00. The stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The company has a 50 day simple moving average of $130.83 and a two-hundred day simple moving average of $134.05. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The firm has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The firm had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter last year, the business posted $2.05 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.

Several analysts recently commented on JNJ shares. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective on the stock in a research note on Thursday, October 17th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Wells Fargo & Co dropped their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 16th. Raymond James dropped their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.